Skip to content
Screener

Exelixis EXEL Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
$00.0%
Tango Therapeutics logo
Tango TherapeuticsTNGX
Incyte logo
IncyteINCY
CTO
Citius Oncology, Inc.CTOR

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$13.12B+30.3%
Enterprise value$13.01B+29.0%
P/E15.3×-1.5×
P/S5.4×+0.9×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemJune 30, 2026December 31, 2025
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 248,885 and 262,483 at June 30, 2026, and December 31, 2025, respectively249262
Additional paid-in-capital2,108,0592,234,411
Accumulated other comprehensive income (loss)(2,013)3,476
Accumulated deficit(262,533)(76,830)
Total stockholders’ equity1,843,7622,161,319

Item 1. Financial Statements.

FAQ

What is Exelixis's common stock, par value (in dollars per share)?
Exelixis (EXEL) reported common stock, par value (in dollars per share) of $0 in Q2 2026.
How has Exelixis's common stock, par value (in dollars per share) changed year-over-year?
Exelixis's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for Exelixis's common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), Exelixis's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.
What does common stock, par value (in dollars per share) mean?
Common stock, par value (in dollars per share)

Ask your AI about Exelixis's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude